Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
about
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibBiomarkers for determining the prognosis in chronic myelogenous leukemiaTyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure.Tyrosine kinase inhibitors and pregnancy.Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaEvolutionary game theory for physical and biological scientists. II. Population dynamics equations can be associated with interpretations.Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.Practical management of patients with chronic myeloid leukemia.Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.Guide to interpreting disease responses in chronic myeloid leukemia.Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical ApproachTargeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell linesImatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).Using functional genomics to overcome therapeutic resistance in hematological malignancies.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaThe choice of first-line chronic myelogenous leukemia treatment.How we will treat chronic myeloid leukemia in 2016.Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Milestones and monitoring.Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR TechniquesThe achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsTreatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experienceComparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapySuboptimal responses in chronic myeloid leukemia: implications and management strategiesChronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring.
P2860
Q26751285-99CEF328-4660-4708-9F26-DC2A2EE565EEQ26824660-F77C4B1B-653E-48B8-8919-C22F87D5443FQ28075963-79AF7D01-E95B-46E9-BE3F-013633605DBAQ31033077-90E891AA-A9DA-45F9-9167-1DDD57AFB859Q33398716-E6547723-DDC3-4B4B-8325-CE47589512A8Q33399867-147D1A1C-5794-4837-89AC-60355F64624FQ33402939-1F5CCF4C-E0B5-4043-8145-3E6E811E670AQ33429973-038EFEA2-D8BD-4264-A5E9-2EBBC87A961AQ33568481-E3837D65-BEE7-4129-B5B6-0B0FF9313CCFQ33806617-04F6856E-58CF-42AB-BC54-1A996192D76EQ33808755-FE65A9F5-6B5B-4073-83CD-BF51559FB30EQ33815980-CEFBE795-16D6-4DFC-8CDA-7F524DAECCC1Q33849146-8DE91892-DEB2-4DAF-8B7D-610B547EA002Q33885583-B69DCF72-FAEE-49EE-87D3-7D00B49FE09CQ33885637-99045C59-ABB9-4BD3-BAF1-FC6F0001B00DQ33888064-7499F01C-9EE5-45B8-923D-2C63DCBC7CCDQ33903030-EA25E50D-ABDF-49DC-A803-1476E5EEB0D4Q33905559-41536192-4879-4676-A11E-A9E8492306C4Q33914049-661D0535-BF9D-4D2E-80BB-2F237B82ECEEQ34022596-10846D0C-3C86-4006-BD77-75F4F7B85ED1Q34155213-102BE279-2C41-483A-80E4-93EE4133F5AEQ34272962-99314545-AC25-4FDB-B7B9-D610997740C4Q34310190-2312B500-900C-4E74-B70C-1ED2729BAA57Q34401328-3F6AB830-D019-4603-A52A-DA68FA0AE28BQ34522789-BF84ACB0-9720-442C-8051-B51810FCCFF1Q34525644-41C10143-CB41-4D3E-AD55-AA2C9A10A8C8Q34639998-EE31E2A3-8873-48FF-B32B-EF81F098C5CAQ34644820-8B4880B5-54B9-4B9D-AE3F-3C2E927913C7Q35221071-5D9EADAD-8E35-4BD7-9FBE-C673D561ECC4Q35269378-6DBDD638-A5CF-4DC9-B893-D976E60B755AQ35560018-51F3695B-53EE-4464-A834-8925FFBA9F7DQ35565658-029B1178-789C-4BD7-9383-5B408086C807Q35652844-B68D6E7A-18B3-4598-A5EA-5A0A4F67A6A5Q35666534-6DBEFD4C-CCC3-4554-8941-2E3978F3BC99Q35674595-3C3CCF32-4144-4341-9B98-42955CC8F58BQ35794115-264C2CC6-CAA9-4D52-B185-698BA1A17072Q35899653-9C67911D-B500-4BE1-8133-DCF9269DF683Q36068354-A408565D-5F9C-4501-B15C-05EBE4006615Q36144079-5564D092-464F-4358-8BE2-F082AC50D509Q36169447-8461781D-BD54-4BF8-A1B5-83201B0AFA84
P2860
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@ast
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@en
type
label
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@ast
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@en
prefLabel
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@ast
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@en
P2093
P2860
P50
P1433
P1476
Long-term prognostic significa ...... f Interferon and STI571 (IRIS)
@en
P2093
Elisabeth Wehrle
IRIS investigators
Jaspal S Kaeda
Jerald P Radich
John M Goldman
Letizia Foroni
Manisha Mone
Marc S Rudoltz
Martin C Müller
Stephen G O'Brien
P2860
P304
P356
10.1182/BLOOD-2010-03-273979
P407
P577
2010-08-02T00:00:00Z